Latest Insider Transactions at Anaptysbio, Inc (ANAB)
This section provides a real-time view of insider transactions for Anaptysbio, Inc (ANAB). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ANAPTYSBIO, INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ANAPTYSBIO, INC's insiders and make more informed investment decisions.
Insider Transaction List
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 21
2024
|
Dennis M Fenton |
SELL
Open market or private sale
|
Direct |
1,950
-50.0%
|
$44,850
$23.17 P/Share
|
Jun 18
2024
|
Hollings Renton |
SELL
Open market or private sale
|
Direct |
1,950
-50.0%
|
$44,850
$23.16 P/Share
|
Jun 15
2024
|
Hollings Renton |
BUY
Exercise of conversion of derivative security
|
Direct |
3,900
+50.0%
|
-
|
Jun 15
2024
|
John A Orwin |
BUY
Exercise of conversion of derivative security
|
Direct |
2,035
+50.0%
|
-
|
Jun 15
2024
|
J. Anthony Ware |
BUY
Exercise of conversion of derivative security
|
Direct |
3,900
+34.21%
|
-
|
Jun 15
2024
|
John P. Schmid |
BUY
Exercise of conversion of derivative security
|
Direct |
3,900
+50.0%
|
-
|
Jun 15
2024
|
Magda Marquet |
BUY
Exercise of conversion of derivative security
|
Direct |
3,900
+50.0%
|
-
|
Jun 15
2024
|
Dennis M Fenton |
BUY
Exercise of conversion of derivative security
|
Direct |
3,900
+50.0%
|
-
|
Jun 15
2024
|
Rita Jain |
BUY
Exercise of conversion of derivative security
|
Direct |
4,534
+50.0%
|
-
|
May 22
2024
|
Dennis Mulroy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,500
-60.88%
|
$34,500
$23.72 P/Share
|
Mar 26
2024
|
Daniel Faga CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
347,441
-46.38%
|
$7,296,261
$21.6 P/Share
|
Mar 25
2024
|
Daniel Faga CEO |
SELL
Open market or private sale
|
Direct |
3,000
-0.4%
|
$63,000
$21.42 P/Share
|
Mar 22
2024
|
Daniel Faga CEO |
SELL
Open market or private sale
|
Direct |
145,940
-16.25%
|
$3,210,680
$22.78 P/Share
|
Feb 16
2024
|
Eric J Loumeau CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
5,000
-60.68%
|
$125,000
$25.0 P/Share
|
Feb 16
2024
|
Eric J Loumeau CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+37.76%
|
$70,000
$14.02 P/Share
|
Jan 30
2024
|
Dennis Mulroy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,065
-76.07%
|
$70,495
$23.63 P/Share
|
Jan 08
2024
|
Daniel Faga CEO |
SELL
Open market or private sale
|
Direct |
6,866
-0.76%
|
$144,186
$21.81 P/Share
|
Jan 08
2024
|
Dennis Mulroy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,180
-35.11%
|
$45,780
$21.81 P/Share
|
Jan 08
2024
|
Eric J Loumeau CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,305
-41.57%
|
$48,405
$21.81 P/Share
|
Jan 08
2024
|
Paul F. Lizzul Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,554
-20.15%
|
$53,634
$21.81 P/Share
|
Jan 06
2024
|
Daniel Faga CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
17,850
+1.93%
|
-
|
Jan 06
2024
|
Dennis Mulroy CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,245
+45.79%
|
-
|
Jan 06
2024
|
Eric J Loumeau CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,545
+50.0%
|
-
|
Jan 06
2024
|
Paul F. Lizzul Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,145
+32.66%
|
-
|
Nov 22
2023
|
Eric J Loumeau CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
882
-100.0%
|
$12,348
$14.19 P/Share
|
Sep 18
2023
|
Dennis Mulroy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,895
-80.16%
|
$74,005
$19.32 P/Share
|
Sep 18
2023
|
Eric J Loumeau CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,895
-81.54%
|
$74,005
$19.32 P/Share
|
Sep 14
2023
|
Paul F. Lizzul Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,105
-24.39%
|
$39,995
$19.48 P/Share
|
Sep 14
2023
|
Paul F. Lizzul Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+41.01%
|
-
|
Sep 14
2023
|
Dennis Mulroy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,105
-30.23%
|
$39,995
$19.48 P/Share
|
Sep 14
2023
|
Dennis Mulroy CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+46.28%
|
-
|
Sep 14
2023
|
Eric J Loumeau CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,105
-30.59%
|
$39,995
$19.48 P/Share
|
Sep 14
2023
|
Eric J Loumeau CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+46.58%
|
-
|
Aug 08
2022
|
Eric J Loumeau CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
523
-100.0%
|
$13,075
$25.0 P/Share
|
Jun 08
2022
|
Eric J Loumeau CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,500
-82.7%
|
$60,000
$24.0 P/Share
|
Jun 08
2022
|
Eric J Loumeau CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+45.27%
|
$35,000
$14.02 P/Share
|
May 18
2022
|
Eric J Loumeau CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,146
-68.66%
|
$22,920
$20.5 P/Share
|
May 05
2022
|
Eco R1 Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
668,237
-8.16%
|
$14,032,977
$21.63 P/Share
|
May 05
2022
|
Eco R1 Capital, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
668,237
+8.16%
|
$14,032,977
$21.63 P/Share
|
Mar 21
2022
|
Daniel Faga CEO |
BUY
Grant, award, or other acquisition
|
Direct |
887,043
+50.0%
|
-
|
Dec 20
2021
|
Hamza Suria President, CEO |
SELL
Open market or private sale
|
Direct |
36,645
-13.12%
|
$1,282,575
$35.68 P/Share
|
Dec 20
2021
|
Hamza Suria President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
36,645
+25.83%
|
$36,645
$1.12 P/Share
|
Nov 15
2021
|
Dennis Mulroy CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
964
+50.0%
|
$21,208
$22.03 P/Share
|
Nov 15
2021
|
Eric J Loumeau CHIEF LEGAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
523
+50.0%
|
$11,506
$22.03 P/Share
|
Nov 15
2021
|
Hamza Suria President, CEO |
BUY
Grant, award, or other acquisition
|
Direct |
964
+1.39%
|
$21,208
$22.03 P/Share
|
Nov 15
2021
|
Paul F. Lizzul Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
964
+50.0%
|
$21,208
$22.03 P/Share
|
Nov 05
2021
|
Hamza Suria President, CEO |
SELL
Open market or private sale
|
Direct |
14,302
-17.45%
|
$500,570
$35.0 P/Share
|
Nov 05
2021
|
Hamza Suria President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
14,302
+14.86%
|
$14,302
$1.12 P/Share
|
Nov 04
2021
|
Eric J Loumeau CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
5,000
-100.0%
|
$175,000
$35.0 P/Share
|
Nov 04
2021
|
Eric J Loumeau CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+41.67%
|
$85,000
$17.09 P/Share
|